Endocrine Abstracts

Introduction: New medicinal products that have been introduced into first-line therapy for type 2 diabetes mellitus (T2DM) include glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl peptidase-4 inhibitors (DPP-4i). These products have been shown to increase beta-cell proliferation. Some studies also demonstrated an increase in pancreatic alpha-cell proliferation. Various sulfonylureas drugs (SU) have been shown to produce different effects on apoptosis pancreat...

Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...